First-Line Pembrolizumab Plus Chemotherapy for Advanced Squamous NSCLC: Real-World Outcomes at U.S. Oncology Practices

INTRODUCTION: Pembrolizumab plus carboplatin and (nab-)paclitaxel (pembrolizumab-chemotherapy) is currently an approved and recommended systemic therapy for patients with previously untreated advanced squamous NSCLC. This retrospective study evaluated real-world time on treatment (rwToT) and overall...

Descripción completa

Detalles Bibliográficos
Autores principales: Liu, Stephen V., Rai, Pragya, Wang, Dong, Hu, Xiaohan, Schwarzenberger, Paul Otto
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2022
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9900616/
https://www.ncbi.nlm.nih.gov/pubmed/36755804
http://dx.doi.org/10.1016/j.jtocrr.2022.100444

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9900616/
https://www.ncbi.nlm.nih.gov/pubmed/36755804
http://dx.doi.org/10.1016/j.jtocrr.2022.100444

Ejemplares similares